TransThera Sciences' (HKG:2617) board approved the conversion of nearly 45 million domestic shares held by 10 shareholders into Hong Kong-listed shares, a Monday Hong Kong bourse filing said.

The shares represent roughly 11.33% of the biopharmaceutical company's issued share capital.

The Hong Kong-listed share full circulation is subject to the finalization of all details, as well as the relevant regulatory approvals.